Supplementary Tables 8 - 15 from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Year: 2023
Type: supplementary-materials
Abstract: PDF file, 127K, S8 IC50s of DPC4/SMAD4 isogenic cells tested with Cisplatin, Irinotecan and Gemcitabine; S9 Correlation analysis between IC50s of Cisplatin, Irinotecan and Gemcitabine and TGFB pathway activity of DPC4 isogenic cells; S10 Genes whose expression levels were correlated with chemosensitivity in pancreatic cancer cell lines; S11 Combination indices (CI) for csplatin+irinotecan combination in DPC4 isogenic cell lines; S12 IC50s of TP53 isogenic colon cancer cell lines tested with Parp1 inhibitor and Triptolide; S13 Comparisons of gene mutation statuses of cell lines having IC50<200nM with those having IC50>10000nM for Parp1 inhibitor; S14 Genes with significantly different gene expression in cell cycle and DNA damage pathway and other DNA damage repair genes without significant difference between TP53 defective PC cell lines having IC50<200nM and those having IC50>10000nM for Parp1 inhibitor; S15 P16/CDKN2A deleted PC cells rank ordered by their sensitivity to gemcitabine and MMC investigated for association with CDKN2B, DMRTA1, MTAP and TUSC1 in pancreatic cancer cells.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361884286